Excelsyn
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | Growth Equity VC | |
$19.0m Valuation: $19.0m | Acquisition | ||
Total Funding | - |
Related Content
Recent News about Excelsyn
EditExcelsyn, operating under the brand AMRI, is a global contract research and manufacturing organization (CRO and CMO) that partners with pharmaceutical and biotechnology companies to enhance patient outcomes and quality of life. The company offers a comprehensive suite of services including drug discovery, development, analytical services, API manufacturing, and drug product solutions. With a presence in North America, Europe, and Asia, Excelsyn leverages scientific expertise and advanced technology to deliver precise solutions tailored to the needs of its clients. The business model revolves around providing specialized services on a contract basis, allowing pharmaceutical and biotech firms to outsource critical aspects of their drug development and manufacturing processes. Revenue is generated through service contracts, project-based fees, and long-term partnerships. Excelsyn serves a diverse range of clients from small biotech startups to large pharmaceutical companies, operating in a highly competitive and regulated market. The company's commitment to quality and precision ensures that projects, regardless of size or complexity, meet stringent industry standards.
Keywords: contract research, manufacturing, drug development, pharmaceutical, biotechnology, API manufacturing, analytical services, drug discovery, global presence, quality assurance.